Biotech stocks rarely perform well during the summer months, and 2019 has proven to be no exception in regards to this historical trend line. The iShares Nasdaq Biotechnology ETF, for example, has now fallen by nearly 2% since the official start of summer.
Biotech equities, however, do generally start to pick up as the year winds down. The underlying reason is… Continue reading at Fool.com